A Phase III, Open-Label Study to Determine the Long-Term Safety and Efficacy of Vedolizumab (MLN0002) in Patients with Ulcerative Colitis and Crohn's Disease04/01/2009 - 09/30/2017 (PI)
Millennium Pharmaceuticals, Inc.
PUCCINI-Prospective Cohort of Ulcerative Colitis and Crohn's Disease Patients Undergoing Surgery to Identify Risk Factors for Post-Operative Infection I06/23/2014 - 07/01/2017 (Subcontract PI)
Icahn School of Medicine at Mount Sinai Crohns & Colitis Fdn
A Study to Assess the Association of Clinical outcome with serum drug concentration levels and anti-drug antibody in moderately to severely active Crohn's Disease patients treated with Adalimumab prot08/01/2011 - 07/31/2012 (PI)
Prometheus Laboratories, Inc.
PROCUREMENT OF BLOOD SAMPLES FROM IBD, GI CONTROLS AND HEALTHY VOLUN TEER SUBJECTS FOR USE IN THE01/01/2011 - 12/31/2011 (PI)
Prometheus Laboratories, Inc.
C13006, A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study for the Induction and Maintenance of Clinical Response and Remission by Vedolizumab (MLN0002) in Patients with Modera04/01/2009 - 05/31/2011 (PI)
Millennium Pharmaceuticals, Inc.
C13007, A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study for the Induction and Maintenance of Clinical Response and Remission by Vedolizuamb (MLN0002) in Patients with Modera04/01/2009 - 05/31/2011 (PI)
Millennium Pharmaceuticals, Inc.
A Phase IIIb Multi-Center, Double-Blind, Placebo-Controlled, Randomized Trial to Examine the Corticosteroid-Sparing Effects of Certolizumab Pegol in Patients with Moderate to Severe Crohn’s Disease (COSPAR I)11/06/2006 - 11/05/2008 (PI)
UCB Pharma, Inc.
A Multi-Center, Open-Label Treatment Protocol of the Human Anti-TNF Monoclonal Antibody Adalimumab in Patients with Moderate to Severe Crohn’s Disease with Previous Exposure to Infliximab12/08/2006 - 06/07/2007 (PI)
Abbott Laboratories
A Randomized, Double-Blind, Placebo-Controlled Clinical Study of the Oral IL-12/23 Inhibitor, STA-5326 Mesylate for the Induction of Clinical Response in Patients with Crohn’s Disease10/06/2005 - 10/05/2006 (PI)
Synta Pharmaceuticals Corporation
An Eight-Week, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate Efficacy and Safety of Talnetant in Subjects with Irritable Bowel Syndrome11/04/2004 - 07/19/2005 (PI)
GlaxoSmithKline, Inc.
Showing 10 of 14 results.
Show All Results
A Phase I/IIa Trial of STA-5326 in Crohn’s Disease Patients With CDAI Scores of 220-400
06/01/2004 - 05/31/2005 (PI)
Synta Pharmaceuticals Corporation
Trial of Rifaximin for the Treatment of Pouchitis
05/12/2003 - 05/11/2004 (PI)
Mayo Clinic Salix Pharmaceutical
Safety & Efficacy of Two Dose Regimens of CBP-1011 (Medroxyprogesterone Acetate, MPA)
05/01/2002 - 04/30/2003 (PI)
InKine Pharmaceutical Company, Inc.
A Phase I/II Randomized Placebo Controlled Double Blind, Parallel Group, Multicenter Study to Determine the Safety, Pharmacokinetics, and Effectiveness of Multiple Doses of LDP 02 in Patients with Mildly to Moderately Active Ulcerative Colitis
04/19/2001 - 03/31/2002 (PI)
Millennium Pharmaceuticals, Inc.
Entyvio (velolizumab) long-term safety study04/12/2016 - 06/30/2023 (Multi-PI)
PI:
Francis A. Farraye, MDTakeda Pharmaceuticals
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Invest to Invest…10/03/2016 - 10/02/2019 (PI)
Celgene Corporation
EH-5151- Evaluating the Nutritional Impact of Serum-Derived Bovine Immunoglobulin / Protein Isola…07/25/2016 - 07/24/2019 (PI)
Entera Health, Inc.
IBD-600 Registry09/19/2018 - 03/31/2019 (PI)
Corrona, LLC
An Open-Label Phase 3b Study to Assess Mucosal Healing in Subjects With Moderately to Severely Ac…10/08/2015 - 09/30/2018 (PI)
Takeda Pharmaceuticals
Sample Collection Study to Evaluate DNA Markers in Subjects with Inflammatory Bowel Disease (IBD)…12/22/2014 - 10/10/2017 (PI)
Exact Sciences
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease:OCEANIA Study12/12/2014 - 06/30/2017 (PI)
Exact Sciences
A Prospective, Randomized,Double Blinded, Placebo-Controlled Phase II Clinical Study of Trichuris…05/01/2014 - 12/31/2015 (PI)
Duke University NIH-NIAID
Host Immune Response to Clostridium Difficile Infection in Inflammatory Bowel Disease12/20/2012 - 09/01/2015 (PI)
Cubist Pharmaceuticals Inc
Methotrexate Response in Treatment of UC - MERIT-UC08/15/2011 - 01/31/2014 (PI)
University of North Carolina NIH-NIDDK
Showing 10 of 13 results.
Show All Results
PIANO: Pregnancy in Inflammatory Bowel Disease & Neonatal Outcomes
07/01/2010 - 12/31/2011 (PI)
Univ of California, San Francisco Crohn's & Colitis Fo
A multicenter prospective study of pregnancy and neonatal health in women with IBD
01/01/2008 - 12/31/2010 (PI)
Univ of California, San Francisco Crohn's & Colitis Fo
A Prospective Single Blinded . . .
01/25/2002 - 12/31/2003 (PI)
Amer Soc Gastro Endoscopy